TrialOpen-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Trial details
- Registry ID
- NCT07637162
- Phase
- Phase 3
Drug research
AXS-14 (esreboxetine)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as AXS-14; esreboxetine
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaNCT07637162 | AXSM | Phase 3 | Enrolling by invitation | 2028-05Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |